Opthea (ASX: OPT) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Opthea Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Opthea (ASX: OPT)
Latest News
Healthcare Shares
'Exciting prospect': 2 ASX pharmaceutical shares to keep a close eye on
Share Fallers
Why Atlas Arteria, Coles, Healius, and Opthea shares are falling today
Share Gainers
Why Appen, Lotus, Opthea, and Paladin Energy shares are surging today
Share Gainers
Why Lotus Resources, Opthea, Qoria, and Sims shares are charging higher today
Share Gainers
Why ARB, Guzman Y Gomez, Opthea, and Yancoal shares are storming higher
Healthcare Shares
2 promising small-cap ASX healthcare stocks to buy now
Speculative
'Blockbuster opportunity': This speculative ASX stock could rise 70%
Share Gainers
Why Atturra, Bravura, Core Lithium, and Opthea shares are racing higher today
Share Fallers
Why Core Lithium, Deterra Royalties, Northern Star, and Opthea shares are dropping
Share Fallers
Why A2 Milk, Lindsay Australia, Meridian Energy, and Opthea shares are falling today
Share Fallers
Why Opthea, Pantoro, Premier Investments, and Wildcat shares are falling
Share Fallers
Why APA Group, Cettire, Deep Yellow, and Opthea shares are falling today
Frequently Asked Questions
-
No, Opthea does not pay shareholder dividends at this time.
-
Opthea Limited listed on the ASX on 18 April 1991.
OPT ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Opthea
Opthea Limited (ASX: OPT) is a clinical-stage biopharmaceutical company. Following the failure of its Phase 3 wet age-related macular degeneration (AMD) trials, the company discontinued that program and relaunched in June 2026 with a new focus on OPT-302 as a potential treatment for lymphangioleiomyomatosis (LAM), a rare lung disease.
Shareholders have been asked to approve a proposed name change to Ceryvyn Therapeutics to reflect the new direction.
OPT Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 08 Jul 2026 | $0.01 | $0.00 | 0.00% | 7,777,329 | $0.01 | $0.02 | $0.01 |
| 07 Jul 2026 | $0.01 | $0.00 | 0.00% | 4,723,387 | $0.02 | $0.02 | $0.01 |
| 06 Jul 2026 | $0.02 | $0.00 | 0.00% | 9,873,809 | $0.02 | $0.02 | $0.01 |
| 03 Jul 2026 | $0.01 | $0.00 | 0.00% | 3,708,050 | $0.02 | $0.02 | $0.01 |
| 02 Jul 2026 | $0.02 | $0.00 | 0.00% | 19,796,064 | $0.02 | $0.02 | $0.01 |
| 01 Jul 2026 | $0.01 | $0.00 | 0.00% | 27,096,878 | $0.02 | $0.02 | $0.01 |